Innovation | Novartis United States of America

Novartis presents pivotal Phase III APPLY-PNH data at ASH demonstrating investigational oral monotherapy iptacopan superiority over anti-C5

Reimagine MedicineInnovation
Novartis investigational iptacopan provides clinically meaningful increases in hemoglobin levels in complement-inhibitor-naïve patients with PNH

Reimagine MedicineInnovation
Novartis Kisqali® prolonged PFS benefit for pre- and perimenopausal patients with aggressive HR+/HER2− metastatic breast cancer compared to chemotherapy

Reimagine MedicineInnovation
Novartis highlights scientific advances with Kisqali, iptacopan, Scemblix and YTB323 data at SABCS and ASH

Reimagine MedicineInnovation
Novartis Scemblix®, with novel mechanism of action, shows superior, long-term efficacy and consistent tolerability in 96-week follow-up of chronic myeloid leukemia trial

Reimagine MedicineInnovation
Novartis expands Beacon of Hope through alliances with Historically Black Medical Schools to address systemic health disparities

Reimagine MedicineInnovation
Novartis presents new four-year data on efficacy and safety of Kesimpta® (ofatumumab) in people living with relapsing multiple sclerosis

Reimagine MedicineInnovation
Novartis acquires Kedalion Therapeutics and its innovative ocular delivery platform that could transform patient experience

Reimagine MedicineInnovation
2004 Release

Reimagine MedicineInnovation
2005 Release

Reimagine MedicineInnovation
News Release 1 Headline

Reimagine MedicineInnovation
Photo: New Data Show Gleevec® Halts Progression to Advanced Stages of Life-Threatening Form of Leukemia in Sixth Year of Treatment

Reimagine MedicineInnovation